It also downregulates the levels of VEGF-A and MMP-9 in serum, suppresses tumor angiogenesis, and increases the sensitivity of mouse breast cancer cells to doxorubicin (DOX) [186]. This evidence concerns the gene VEGFA and breast cancer.